title: Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab.
abstract: Severe side effects and few long-term remissions frequently limit the treatment of advanced malignant diseases. Bispecific antibodies are currently emerging as a new option for the treatment of malignant diseases, which can potentially engage all cytotoxic T cells of a patient for tumor cell lysis. Blinatumomab, a bispecific single-chain BiTE antibody construct with dual specificity for CD19 and CD3, is a front runner of this antibody class. We here summarize the current state of development of blinatumomab for the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL) and B-precursor acute lymphocytic leukemia (ALL). High response rates and durable remissions are observed in first clinical trials, indicating that T cells can be potently redirected for efficient and lasting elimination of malignant cells.
authors.affiliation: Micromet, Inc, 6707 Democracy Blvd, Bethesda, MD 20817, USA. dirk.nagorsen@micromet.com
authors.forename: Dirk
authors.initials: D
authors.lastname: Nagorsen
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Baeuerle
mesh_terms: D018033:Antibodies, Bispecific / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D056747:Immunomodulation; D007945:Leukemia, Lymphoid / Q000276:immunology* / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D018033:Antibodies, Bispecific; C510808:blinatumomab